Register to receive a free U.S. Market Report Suite for Immunology Drugs report synopsis and brochure

Amgen recently announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding AMGEVITA™/AMJEVITA™, a biosimilar to AbbVie’s Humira® (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of AMGEVITA/AMJEVITA worldwide, on a country-by-country basis, and the companies have agreed to dismiss all pending litigation. Amgen expects to launch AMGEVITA in Europe on Oct. 16, 2018, and AMJEVITA in the United States on Jan. 31, 2023.

Under the terms of the settlement agreements, AbbVie will grant to Amgen a non-exclusive license to AbbVie’s intellectual property relating to HUMIRA beginning on certain dates in certain countries in which AbbVie has intellectual property. Amgen will pay royalties as specified under the agreements. The precise terms are confidential between the parties. All litigation pending between the parties will be dismissed, and Amgen has acknowledged the validity of AbbVie’s intellectual property related to HUMIRA.

“We look forward to leveraging our existing biologics capabilities to bring high-quality biosimilars to patients worldwide. AMGEVITA will be one of our first biosimilar launches, and this agreement will allow us to secure a strong foothold in the $4 billion European adalimumab market,” said Scott Foraker, vice president and general manager of Biosimilars at Amgen. “Building on our strong inflammatory disease presence in the United States, we are excited to develop our inflammation capabilities in Europe, extending our reach and helping more patients gain access to this important class of therapies.”

“We are pleased to have reached this settlement with Amgen which respects the breadth and strength of our intellectual property portfolio,” said Laura Schumacher, executive vice president, external affairs, general counsel and corporate secretary, AbbVie. “As an innovation driven bio-pharmaceutical company, we believe intellectual property is essential to protect the investment in science and advance novel cures for the toughest health challenges. In reaching this agreement, we have achieved the balance between protecting investment in innovation and providing access to biosimilars, which will play an important role in our health care system. We will continue to defend our intellectual property and to reinvest in further advancements in medicine to bring choices to patients in need.”

For Further Information
The Immunology Drugs Market Report Suite covers reports on the following markets: Rheumatoid Arthritis Treatment, Crohn’s Disease Treatment, Psoriasis Treatment, Ankylosing Spondylitis Treatment and Ulcerative Colitis Treatment.

The iData report series on immunology drugs covers the U.S., Canada, Brazil, Russia, India, China, Japan, U.K. Germany, Spain, Italy and France. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about immunology drug market data, register online or email us at [email protected] for a U.S. Market Report Suite for Immunology Drugs brochure and synopsis.